| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery (NCT02455791) | M.D. Anderson Cancer Center | 2015-06-24 |
| Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients (NCT02481297) | M.D. Anderson Cancer Center | 2015-06-23 |
| Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC) (NCT02389764) | M.D. Anderson Cancer Center | 2015-06-22 |
| Time From Onset of Fever to Administration of Antibiotics in Neutropenic Fever Patients (NCT03968328) | M.D. Anderson Cancer Center | 2015-06-19 |
| Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation (NCT02420912) | M.D. Anderson Cancer Center | 2015-06-19 |
| Couples-Based Yoga Program in Improving Quality of Life in Patients With High-Grade Glioma Undergoing Radiation Therapy and Their Partners (NCT02481349) | M.D. Anderson Cancer Center | 2015-06-16 |
| Tc99m Sestamibi Molecular Breast Imaging (NCT02324387) | M.D. Anderson Cancer Center | 2015-06-15 |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) (NCT02410551) | M.D. Anderson Cancer Center | 2015-06-15 |
| Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy (NCT02411656) | M.D. Anderson Cancer Center | 2015-06-11 |
| Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT02427620) | M.D. Anderson Cancer Center | 2015-06-03 |
| Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02316834) | M.D. Anderson Cancer Center | 2015-06-02 |
| Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma (NCT02241668) | M.D. Anderson Cancer Center | 2015-06-01 |
| Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) (NCT02169505) | M.D. Anderson Cancer Center | 2015-05-22 |
| Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma (NCT02293005) | M.D. Anderson Cancer Center | 2015-05-20 |
| Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure (NCT02159872) | M.D. Anderson Cancer Center | 2015-05-18 |
| Varenicline and Combined NRT for Smoking Cessation (NCT02271919) | M.D. Anderson Cancer Center | 2015-05-14 |
| Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis (NCT02421354) | M.D. Anderson Cancer Center | 2015-05-14 |
| An Open-label Phase II Study of Lorvotuzumab Mertansine (NCT02420873) | M.D. Anderson Cancer Center | 2015-05-12 |
| Compassionate Access of the Miltenyi Device for CD34+ Cell Selection (NCT02438904) | M.D. Anderson Cancer Center | 2015-05-06 |
| Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) (NCT02141477) | M.D. Anderson Cancer Center | 2015-05-06 |
| CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia (NCT02286726) | M.D. Anderson Cancer Center | 2015-05-04 |
| Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention (NCT02422329) | M.D. Anderson Cancer Center | 2015-04-30 |
| Measuring Surgical Recovery After Radical Cystectomy (NCT03193970) | M.D. Anderson Cancer Center | 2015-04-30 |
| Pembrolizumab in Treating Patients With Recurrent Glioblastoma (NCT02337686) | M.D. Anderson Cancer Center | 2015-04-28 |
| Ultraviolet (UV) Photography in Adolescents (NCT02426853) | M.D. Anderson Cancer Center | 2015-04-21 |
| Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT02399917) | M.D. Anderson Cancer Center | 2015-04-20 |
| Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma (NCT02269085) | M.D. Anderson Cancer Center | 2015-04-20 |
| Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer (NCT02282345) | M.D. Anderson Cancer Center | 2015-04-16 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML (NCT02311998) | M.D. Anderson Cancer Center | 2015-04-16 |
| Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT02420860) | M.D. Anderson Cancer Center | 2015-04-14 |
| Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families (NCT02337452) | M.D. Anderson Cancer Center | 2015-04-10 |
| Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) (NCT03043508) | M.D. Anderson Cancer Center | 2015-04-10 |
| Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer (NCT02389751) | M.D. Anderson Cancer Center | 2015-04-10 |
| Massage Therapy in Reducing Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastrointestinal or Breast Malignancies (NCT02221700) | M.D. Anderson Cancer Center | 2015-04-09 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (NCT02397720) | M.D. Anderson Cancer Center | 2015-04-07 |
| Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer (NCT02225405) | M.D. Anderson Cancer Center | 2015-04-03 |
| Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers (NCT02392637) | M.D. Anderson Cancer Center | 2015-04-02 |
| Prospective Study of Colonoscopic Resection of Large Polyps and Flat Lesions (NCT02332772) | M.D. Anderson Cancer Center | 2015-04-01 |
| A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NCT02321540) | M.D. Anderson Cancer Center | 2015-03-31 |
| Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission (NCT02302846) | M.D. Anderson Cancer Center | 2015-03-20 |
| High-Flow Oxygen in Reducing Shortness of Breath Caused by Exercise in Patients With Cancer (NCT02357134) | M.D. Anderson Cancer Center | 2015-03-17 |
| Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors (NCT02271711) | M.D. Anderson Cancer Center | 2015-03-17 |
| An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) (NCT02225574) | M.D. Anderson Cancer Center | 2015-03-11 |
| Cordotomy for Refractory Cancer Pain (NCT02345629) | M.D. Anderson Cancer Center | 2015-03-10 |
| Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer (NCT02361320) | M.D. Anderson Cancer Center | 2015-03-09 |
| Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases (NCT02387905) | M.D. Anderson Cancer Center | 2015-03-09 |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma (NCT02280525) | M.D. Anderson Cancer Center | 2015-03-05 |
| Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation (NCT02210065) | M.D. Anderson Cancer Center | 2015-03-03 |
| PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening (NCT02286713) | M.D. Anderson Cancer Center | 2015-03-01 |
| C-VISA BikDD: Liposome in Advanced Pancreatic Cancer (NCT00968604) | M.D. Anderson Cancer Center | 2015-03-01 |
| Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma (NCT01209871) | M.D. Anderson Cancer Center | 2015-02-26 |
| Metformin in Non Small Cell Lung Cancer (NSCLC) (NCT02285855) | M.D. Anderson Cancer Center | 2015-02-20 |
| Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection (NCT02210078) | M.D. Anderson Cancer Center | 2015-02-19 |
| Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery (NCT02302833) | M.D. Anderson Cancer Center | 2015-02-17 |
| Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia (NCT02257138) | M.D. Anderson Cancer Center | 2015-02-12 |
| Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer (NCT02366130) | M.D. Anderson Cancer Center | 2015-02-11 |
| Denosumab for Breast Cancer With Bone Mets (NCT01952054) | M.D. Anderson Cancer Center | 2015-02-09 |
| Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation (NCT02196857) | M.D. Anderson Cancer Center | 2015-02-06 |
| Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer (NCT02295956) | M.D. Anderson Cancer Center | 2015-02-02 |
| Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease (NCT02378701) | M.D. Anderson Cancer Center | 2015-02-01 |
| Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (NCT01740557) | M.D. Anderson Cancer Center | 2015-01-28 |
| Mindfulness Based Couples Therapy (NCT02349217) | M.D. Anderson Cancer Center | 2015-01-23 |
| CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (NCT02027935) | M.D. Anderson Cancer Center | 2015-01-22 |
| Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma (NCT02106988) | M.D. Anderson Cancer Center | 2015-01-16 |
| Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT02199184) | M.D. Anderson Cancer Center | 2015-01-14 |
| Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) (NCT02267278) | M.D. Anderson Cancer Center | 2015-01-12 |
| A Culturally Sensitive Social Support Intervention (NCT02946697) | M.D. Anderson Cancer Center | 2015-01-01 |
| Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) (NCT02194374) | M.D. Anderson Cancer Center | 2015-01-01 |
| Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study (NCT02302859) | M.D. Anderson Cancer Center | 2015-01-01 |
| Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes (NCT02286687) | M.D. Anderson Cancer Center | 2014-12-22 |
| LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis (NCT02098161) | M.D. Anderson Cancer Center | 2014-12-18 |
| Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery (NCT02210117) | M.D. Anderson Cancer Center | 2014-11-25 |
| Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (NCT01924169) | M.D. Anderson Cancer Center | 2014-11-24 |
| ICU Triage Practices in a Cancer Hospital (NCT03401411) | M.D. Anderson Cancer Center | 2014-11-17 |
| Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission (NCT02126553) | M.D. Anderson Cancer Center | 2014-11-13 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian (NCT02208375) | M.D. Anderson Cancer Center | 2014-11-11 |
| Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia (NCT02292368) | M.D. Anderson Cancer Center | 2014-11-10 |
| LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma (NCT02138929) | M.D. Anderson Cancer Center | 2014-11-10 |
| Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes (NCT02131597) | M.D. Anderson Cancer Center | 2014-11-10 |
| Rational Therapeutics Based on Matched Tumor and Normal Tissue (NCT02272595) | M.D. Anderson Cancer Center | 2014-11-04 |
| Exploring the Neuro-Immune Basis of Cancer-Related Fatigue Using Behavioral Measures (NCT02255773) | M.D. Anderson Cancer Center | 2014-11-04 |
| Prospective Study of Colon Serrated Polyps (NCT02332785) | M.D. Anderson Cancer Center | 2014-11-01 |
| Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer (NCT02140021) | M.D. Anderson Cancer Center | 2014-10-27 |
| Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT02250937) | M.D. Anderson Cancer Center | 2014-10-27 |
| Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (NCT02135874) | M.D. Anderson Cancer Center | 2014-10-27 |
| Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation (NCT02231775) | M.D. Anderson Cancer Center | 2014-10-22 |
| PCORI-CER-1306-03385 Lung Cancer Screening Readiness Study (NCT02292485) | M.D. Anderson Cancer Center | 2014-10-20 |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells (NCT02274506) | M.D. Anderson Cancer Center | 2014-10-20 |
| Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma (NCT01955460) | M.D. Anderson Cancer Center | 2014-10-15 |
| Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) (NCT02269280) | M.D. Anderson Cancer Center | 2014-10-13 |
| Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions (NCT02156739) | M.D. Anderson Cancer Center | 2014-10-13 |
| Diagnostic Aids for Detection and Diagnosis of Oral Cancer (NCT02251639) | M.D. Anderson Cancer Center | 2014-10-01 |
| AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT02420587) | M.D. Anderson Cancer Center | 2014-10-01 |
| 18-F-Fluoroacetate as PET Imaging Agent (NCT01320787) | M.D. Anderson Cancer Center | 2014-10-01 |
| Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking (NCT02130453) | M.D. Anderson Cancer Center | 2014-09-30 |
| Yoga Program for Lung Cancer Patients and Caregivers (NCT02196844) | M.D. Anderson Cancer Center | 2014-09-29 |
| Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma (NCT02225496) | M.D. Anderson Cancer Center | 2014-09-23 |
| Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases (NCT02135484) | M.D. Anderson Cancer Center | 2014-09-19 |
| Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members (NCT02194387) | M.D. Anderson Cancer Center | 2014-09-17 |